aTENSION.life, a high-tech health startup based in Vienna, Austria, has raised $3 million in seed funding to develop advanced tools for diagnosing high blood pressure more accurately.
The funding round was led by Wlanholding, with support from eQventure and VP Venture Partners. As part of the deal, Dr. Werner Lanthaler, the Founder and CEO of Wlanholding, has been named Chairman of the Supervisory Board at aTENSION.life.
aTENSION.life has created a special technology called ALDO+ that uses advanced mass spectrometry to help diagnose high blood pressure more accurately. This makes it easier for patients with uncontrolled hypertension to get the right treatment.
The company’s first product, ALDO+PA, is designed to detect primary aldosteronism—a health problem that causes high blood pressure and is often missed. It affects around 5–10% of people with hypertension.
The ALDO+PA test is already available in Austria through a partnership with laborers, helping doctors better detect a hidden cause of high blood pressure.
The company plans to expand the test to Germany, Switzerland, and other DACH countries by 2026. Some customers in Germany, Switzerland, and the US have already started using the technology.
Dr. Lanthaler will provide strategic guidance to aTENSION. Life’s newly announced management team: Bernhard Klemen (CEO), Marko Poglitsch (CSO), and Katharina Wieser (CBO).
Read more- Bolttech and Sumitomo Partner to Provide Tech-Driven Solutions to Distribution Partners in Asia
